Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
11 September 2023 - 1:00PM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced the appointment of James Robinson to its Board of
Directors effective October 1, 2023. Mr. Robinson is a seasoned
biopharmaceutical executive with over 30 years of experience in the
industry, most recently serving as Chief Executive Officer and
Director of Urovant Sciences until its merger with Sumitomo Pharma
America on July 1, 2023.
“I am pleased to welcome Jim to our Board and look
forward to working with him,” said David-Alexandre C. Gros, M.D.,
Chief Executive Officer. “Jim joins our Board at a pivotal time in
our mission to bring a novel and much-needed new treatment option
to the growing number of patients undergoing kidney
transplantation. His experience as a leader in the
biopharmaceutical industry will be invaluable in this next phase of
Eledon’s trajectory.”
As Chief Executive Officer and Director of Urovant
Sciences, Mr. Robinson guided the company through FDA approval of
its first drug, a successful product launch, and its acquisition
and “take-private” transaction by Sumitomo Dainippon Pharma. Prior
to Urovant, he was President and Chief Operating Officer of Paragon
Biosciences. Before his time at Paragon, Mr. Robinson served as
President and COO of Alkermes, leading operations that generated
more than $1 billion in annual revenue. Prior to Alkermes, Mr.
Robinson spent over 12 years at Astellas Pharma, one of the leaders
in the field of solid organ transplant, where he served as
President of the Americas and was responsible for approximately $4
billion in revenue generation.
Mr. Robinson currently serves on the Board of
Directors of UroGen Pharma (Nasdaq: URGN). He previously served on
the Board of Directors for Neos Therapeutics and for AGTC before
the company was sold to Syncona. Mr. Robinson also previously
served on the Board of Directors of the Pharmaceutical Research and
Manufacturers of America (PhRMA), where he served as Chairman of
PhRMA’s State Committee. He earned a Bachelor of Science in
marketing from DePaul University.
“I am inspired by Eledon’s mission to address a
therapeutic area with thousands of patients in need of a better
option to protect their transplanted organs,” said Mr. Robinson.
“Backed by strong scientific rationale and promising clinical
results to date, tegoprubart has the potential to change the
outlook for patients with transplanted kidneys and help alleviate
shortages of available kidneys by preserving the kidneys in
transplant patients. I look forward to leveraging my background and
experience while working closely with the Eledon management team to
continue advancing tegoprubart through the clinic.”
About Eledon Pharmaceuticals and
tegoprubart
Eledon Pharmaceuticals is a clinical stage
biotechnology company with immunology expertise that is developing
therapies to protect and prevent rejection of transplanted organs,
as well as to treat amyotrophic lateral sclerosis (ALS). The
Company’s lead compound in development is tegoprubart, an
anti-CD40L antibody with high affinity for CD40 Ligand, a
well-validated biological target with broad therapeutic potential.
Eledon is headquartered in Irvine, California. For more
information, please visit the company’s website
at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. Any
statements about planned clinical trials and the Company’s other
future expectations, plans and prospects, as well as other
statements containing the words “believes,” “anticipates,” “plans,”
“expects,” “estimates,” “intends,” “predicts,” “projects,”
“targets,” “looks forward,” “could,” “may,” and similar
expressions, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are inherently uncertain and are subject
to numerous risks and uncertainties, including: risks relating to
the safety and efficacy of our drug candidates; risks relating to
clinical development timelines, including interactions with
regulators and clinical sides, as well as patient enrollment; risks
relating to costs of clinical trials and the sufficiency of the
company’s capital resources to fund planned clinical trials; and
risks associated with the impact of the ongoing coronavirus
pandemic. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various factors.
These risks and uncertainties, as well as other risks and
uncertainties that could cause the company’s actual results to
differ significantly from the forward-looking statements contained
herein, are discussed in our quarterly 10-Q, annual 10-K, and other
filings with the U.S. Securities and Exchange Commission,
which can be found at www.sec.gov. Any forward-looking
statements contained in this press release speak only as of the
date hereof and not of any future date, and the company expressly
disclaims any intent to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public
Relations(212) 253 8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024